Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results...

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Trials

Background:

• Rheumatoid arthritis (RA) management often involves optimizing drug dosages.
• Baricitinib is a Janus kinase (JAK) inhibitor used for RA treatment.
• Sustained disease control is a key goal in RA therapy.

Purpose of the Study:

• To evaluate the efficacy of dose reduction from baricitinib 4 mg to 2 mg in RA patients with sustained low disease activity (LDA) or remission (REM).
• To assess the maintenance of disease control and the need for dose escalation or rescue therapy.

Main Methods:

• A long-term extension (LTE) study involving RA patients treated with baricitinib 4 mg.
• Patients achieving LDA/REM for at least 15 months were randomized to continue 4 mg or switch to 2 mg.
• Rescue strategies included increasing to 4 mg or adding conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
• Efficacy was assessed over 96 weeks using the Clinical Disease Activity Index (CDAI) with nonresponder imputation (NRI).

Main Results:

• At 96 weeks, 70.2% of patients on 4 mg maintained LDA versus 59.9% on 2 mg (NRI).
• Remission rates were 36.6% for 4 mg and 30.8% for 2 mg.
• Rescue rates were 14.7% for the 4-mg group and 22.5% for the 2-mg group.
• Of those who lost LDA on 2 mg and were rescued to 4 mg, 76.2% regained LDA within 12 weeks.

Conclusions:

• Continued baricitinib 4 mg daily provides superior maintenance of LDA/REM in RA patients compared to tapering to 2 mg.
• A significant proportion of patients (76%) can maintain or recapture LDA/REM when switched back to 4 mg if needed.
• Dose tapering to 2 mg is a viable option for some RA patients, with a clear rescue pathway available.